Cognitive consequences of a sustained monocyte type 1 IFN response in HIV-1 infection

Current HIV Research

Volumn 12, Issue 2, 2014, Pages 77-84

  Pulliam, Lynn ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cognition; HCV; HIV 1; Impairment; Interferon; Monocyte

Indexed keywords

ALPHA INTERFERON; CD16 ANTIGEN; CD163 ANTIGEN; CXCL3 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; SIALOADHESIN; ANTIVIRUS AGENT;

ARTICLE; AUTOIMMUNE DISEASE; CELL INFILTRATION; CELL PROLIFERATION; COGNITIVE DEFECT; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; INFLAMMATION; MACROPHAGE; MIXED INFECTION; MONOCYTE; NONHUMAN; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; VIREMIA; ANIMAL; COGNITION; DRUG EFFECTS; HIV INFECTIONS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIVIRAL AGENTS; COGNITION; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MONOCYTES;

EID: 84905649636     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X12666140526113544     Document Type: Article

References (76)

1. Harezlak J, Buchthal S, Taylor M, et al. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS 2011; 25(5): 625-33.
2. Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PloS one 2008; 3(6): e2516.
3. Rempel H, Sun B, Calosing C, et al. Interferon-alpha drives monocyte gene expression in chronic unsuppressed HIV-1 infection AIDS 2010; 24(10): 1415-23.
4. Redd AD, Dabitao D, Bream JH, et al. Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. Proceedings of the National Academy of Sciences of the United States of America 2009; 106(16): 6718-23.
5. Redd AD, Gray RH, Quinn TC. Is microbial translocation a cause or consequence of HIV disease progression? The Journal of infectious diseases 2011; 203(5): 744-5; author reply 6.
6. Der SD, Zhou A, Williams BR, et al. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proceedings of the National Academy of Sciences of the United States of America 1998; 95(26): 15623-8.
7. Theofilopoulos AN, Baccala R, Beutler B, et al. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005; 23: 307-36.
8. Donnelly RP, Kotenko SV. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 2010; 30(8): 555-64.
9. Hartshorn KL, Neumeyer D, Vogt MW, et al. Activity of interferons alpha, beta, and gamma against human immunodeficiency virus replication in vitro. AIDS Res Hum Retroviruses 1987; 3(2): 125-33.
10. Witwer KW, Gama L, Li M, et al. Coordinated regulation of SIV replication and immune responses in the CNS. PloS one 2009; 4(12): e8129.
11. Alammar L, Gama L, Clements JE. Simian immunodeficiency virus infection in the brain and lung leads to differential type I IFN signaling during acute infection. J Immunol 2011; 186(7): 4008-18.
12. Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284(5421): 1835-7.
13. Fitzgerald-Bocarsly P, Jacobs ES. Plasmacytoid dendritic cells in HIV infection: striking a delicate balance. Journal of leukocyte biology 2010; 87(4): 609-20.
14. von Sydow M, Sonnerborg A, Gaines H, et al. Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. AIDS Res Hum Retroviruses 1991; 7(4): 375-80.
15. Khatissian E, Tovey MG, Cumont MC, et al. The relationship between the interferon alpha response and viral burden in primary SIV infection. AIDS Res Hum Retroviruses 1996; 12(13): 1273-8.
16. Tilton JC, Johnson AJ, Luskin MR, et al. Diminished production of monocyte proinflammatory cytokines during human immunodeficiency virus viremia is mediated by type I interferons. J Virol. 2006; 80(23): 11486-97.
17. Pulliam L, Rempel H, Sun B, et al. A peripheral monocyte interferon phenotype in HIV infection correlates with a decrease in magnetic resonance spectroscopy metabolite concentrations. AIDS 2011; 25(14): 1721-6.
18. Chahroudi A, Bosinger SE, Vanderford TH, et al. Natural SIV hosts: showing AIDS the door. Science 2012; 335(6073): 1188-93.
19. Hirsch VM. What can natural infection of African monkeys with simian immunodeficiency virus tell us about the pathogenesis of AIDS? AIDS reviews 2004; 6(1): 40-53.
20. Silvestri G, Sodora DL, Koup RA, et al. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003; 18(3): 441-52.
21. Sumpter B, Dunham R, Gordon S, et al. Correlates of preserved CD4(+) T cell homeostasis during natural, nonpathogenic simian immunodeficiency virus infection of sooty mangabeys: implications for AIDS pathogenesis. J Immunol 2007; 178(3): 1680-91.
22. Chakrabarti LA, Lewin SR, Zhang L, et al. Normal T-cell turnover in sooty mangabeys harboring active simian immunodeficiency virus infection. J Virol 2000; 74(3): 1209-23.
23. Silvestri G, Fedanov A, Germon S, et al. Divergent host responses during primary simian immunodeficiency virus SIVsm infection of natural sooty mangabey and nonnatural rhesus macaque hosts. J Virol 2005; 79(7): 4043-54.
24. Bosinger SE, Li Q, Gordon SN, et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. The Journal of clinical investigation 2009; 119(12): 3556-72.
25. Manches O, Bhardwaj N. Resolution of immune activation defines nonpathogenic SIV infection. The Journal of clinical investigation 2009; 119(12): 3512-5.
26. Jaroenpool J, Rogers KA, Pattanapanyasat K, et al. Differences in the constitutive and SIV infection induced expression of Siglecs by hematopoietic cells from non-human primates. Cellular immunology 2007; 250(1/2): 91-104.
27. Rempel H, Calosing C, Sun B, et al. Sialoadhesin expressed on IFN-induced monocytes binds HIV-1 and enhances infectivity. PloS one 2008; 3(4): e1967.
28. Stylianou E, Aukrust P, Bendtzen K, et al. Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection. Clinical and experimental immunology 2000; 119(3): 479-85.
29. Fear WR, Kesson AM, Naif H, et al. Differential tropism and chemokine receptor expression of human immunodeficiency virus type 1 in neonatal monocytes, monocyte-derived macrophages, and placental macrophages. J Virol 1998; 72(2): 1334-44.
30. Schuitemaker H, Kootstra NA, Koppelman MH, et al. Proliferation-dependent HIV-1 infection of monocytes occurs during differentiation into macrophages. The Journal of clinical investigation 1992; 89(4): 1154-60.
31. Pulliam L, Herndier BG, Tang NM, et al. Human immunodeficiency virus-infected macrophages produce soluble factors that cause histological and neurochemical alterations in cultured human brains. The Journal of clinical investigation 1991; 87(2): 503-12.
32. Pulliam L, Gascon R, Stubblebine M, et al. Unique monocyte subset in patients with AIDS dementia. Lancet 1997; 349(9053): 692-5.
33. Pulliam L, Sun B, Rempel H. Invasive chronic inflammatory monocyte phenotype in subjects with high HIV-1 viral load. J Neuroimmunol 2004; 157(1/2): 93-8.
34. Buckner CM, Calderon TM, Willams DW, et al. Characterization of monocyte maturation/differentiation that facilitates their transmigration across the blood-brain barrier and infection by HIV: implications for NeuroAIDS. Cellular immunology 2011; 267(2): 109-23.
35. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. Journal of leukocyte biology 2007; 81(3): 584-92.
36. Ellery PJ, Tippett E, Chiu YL, et al. The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol 2007; 178(10): 6581-9.
37. Fischer-Smith T, Croul S, Sverstiuk AE, et al. CNS invasion by CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection. Journal of neurovirology 2001; 7(6): 528-41.
38. Fischer-Smith T, Bell C, Croul S, et al. Monocyte/macrophage trafficking in acquired immunodeficiency syndrome encephalitis: lessons from human and nonhuman primate studies. Journal of neurovirology 2008; 14(4): 318-26.
39. Kim WK, Alvarez X, Fisher J, et al. CD163 identifies perivascular macrophages in normal and viral encephalitic brains and potential precursors to perivascular macrophages in blood. The American journal of pathology 2006; 168(3): 822-34.
40. Kim N, Kukkonen S, Martinez-Viedma Mdel P, et al. Tat engagement of p38 MAP kinase and IRF7 pathways leads to activation of interferon-stimulated genes in antigen-presenting cells. Blood 2013; 121(20): 4090-100.
41. Imamichi T, Yang J, Huang DW, et al. IL-27, a novel anti-HIV cytokine, activates multiple interferon-inducible genes in macrophages. Aids 2008; 22(1): 39-45.
42. Chen Q, Swaminathan S, Yang D, et al. Interleukin-27 is a potent inhibitor of cis HIV-1 replication in monocyte-derived dendritic cells via a type I interferon-independent pathway. PloS one 2013; 8(3): e59194.
43. Burdo TH, Weiffenbach A, Woods SP, et al. Elevated sCD163 is a marker of neurocognitive impairment in HIV infection. Aids 2013.
44. Huber C, Batchelor JR, Fuchs D, et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984; 160(1): 310-6.
45. Kamat A, Lyons JL, Misra V, et al. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. Journal of acquired immune deficiency syndromes 2012; 60(3): 234-43.
46. Yuan L, Qiao L, Wei F, et al. Cytokines in CSF correlate with HIV-associated neurocognitive disorders in the post-HAART era in China. Journal of neurovirology 2013; 19(2): 144-9.
47. Kamat A, Misra V, Cassol E, et al. A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy. PloS one 2012; 7(2): e30881.
48. Fritz-French C, Tyor W. Interferon-alpha (IFNalpha) neurotoxicity. Cytokine & growth factor reviews 2012; 23(1/2): 7-14.
49. Myint AM, Schwarz MJ, Steinbusch HW, et al. Neuropsychiatric disorders related to interferon and interleukins treatment. Metabolic brain disease 2009; 24(1): 55-68.
50. Smith A, Tyrrell D, Coyle K, et al. Effects of interferon alpha on performance in man: a preliminary report. Psychopharmacology 1988; 96(3): 414-6.
51. Sas AR, Bimonte-Nelson H, Smothers CT, et al. Interferon-alpha causes neuronal dysfunction in encephalitis. The Journal of neuroscience: the official journal of the Society for Neuroscience 2009; 29(12): 3948-55.
52. Sun B, Abadjian L, Rempel H, et al. Differential cognitive impairment in HCV coinfected men with controlled HIV compared to HCV monoinfection. Journal of acquired immune deficiency syndromes 2013; 62(2): 190-6.
53. Rempel H, Sun B, Calosing C, et al. Monocyte activation in HIV/HCV coinfection correlates with cognitive impairment. PloS one 2013; 8(2): e55776.
54. Higgs BW, Liu Z, White B, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Annals of the rheumatic diseases 2011; 70(11): 2029-36.
55. Ronnblom L, Eloranta ML. The interferon signature in autoimmune diseases. Current opinion in rheumatology 2013; 25(2): 248-53.
56. Raterman HG, Vosslamber S, de Ridder S, et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis research & therapy 2012; 14(2): R95.
57. Verweij CL, Vosslamber S. New insight in the mechanism of action of rituximab: the interferon signature towards personalized medicine. Discovery medicine. 2011; 12(64): 229-36.
58. Thurlings RM, Boumans M, Tekstra J, et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis and rheumatism 2010; 62(12): 3607-14.
59. Appenzeller S, Bertolo MB, Costallat LT. Cognitive impairment in rheumatoid arthritis. Methods and findings in experimental and clinical pharmacology 2004; 26(5): 339-43.
60. Sciascia S, Bertolaccini ML, Baldovino S, et al. Central nervous system involvement in systemic lupus erythematosus: Overview on classification criteria. Autoimmunity reviews 2013; 12(3): 426-9.
61. Kozora E, Hanly JG, Lapteva L, et al. Cognitive dysfunction in systemic lupus erythematosus: past, present, and future. Arthritis and rheumatism 2008; 58(11): 3286-98.
62. Popescu A, Kao AH. Neuropsychiatric systemic lupus erythematosus. Current neuropharmacology 2011; 9(3): 449-57.
63. Biesen R, Demir C, Barkhudarova F, et al. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis and rheumatism 2008; 58(4): 1136-45.
64. Kirou KA, Gkrouzman E. Anti-interferon alpha treatment in SLE. Clinical immunology 2013.
65. High KP, Brennan-Ing M, Clifford DB, et al. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. Journal of acquired immune deficiency syndromes. 2012; 60(Suppl 1): S1-18.
66. Gringeri A, Santagostino E, Mannucci PM, et al. A randomized, placebo-controlled, blind anti-AIDS clinical trial: safety and immunogenicity of a specific anti-IFN alpha immunization. Journal of acquired immune deficiency syndromes 1994; 7(9): 978-88.
67. Fall LS, M'Bika JP, Le Coq H, et al. Biological effect of active anti-IFN alpha immunization in HIV-infected patients. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 1995; 49(9): 422-8.
68. Gringeri A, Santagostino E, Cusini M, et al. Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up report. Journal of acquired immune deficiency syndromes and human retrovirology: official publication of the International Retrovirology Association 1996; 13(1): 55-67.
69. Gringeri A, Musicco M, Hermans P, et al. Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study). Journal of acquired immune deficiency syndromes and human retrovirology: official publication of the International Retrovirology Association 1999; 20(4): 358-70.
70. Zagury D, Lecoq H, Gervi I, et al. Anti-IFN alpha immunization raises the IFN alpha-neutralizing capacity of serum--an adjuvant to antiretroviral tritherapy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 1999; 53(2): 90-2.
71. Wilson EB, Yamada DH, Elsaesser H, et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013; 340(6129): 202-7.
72. Teijaro JR, Ng C, Lee AM, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013; 340(6129): 207-11.
73. Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis and rheumatism 2013; 65(4): 1011-21.
74. Ding HJ, Gordon C. New biologic therapy for systemic lupus erythematosus. Current opinion in pharmacology 2013.
75. Lauwerys BR, Hachulla E, Spertini F, et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis and rheumatism 2013; 65(2): 447-456.
76. d'Ettorre G, Paiardini M, Ceccarelli G, et al. HIV-associated immune activation: from bench to bedside. AIDS Res Hum Retroviruses 2011; 27(4): 355-364